Wesley A. Mayer, MD, presented “The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell Carcinoma” during the 23rd Annual Innovations in Urologic Practice on September 14, 2018 in Santa Fe, New Mexico.

How to cite: Mayer, Wesley A.. “The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell Carcinoma?” September 14, 2018. Accessed Jun 2019. https://grandroundsinurology.com/the-bottom-line-practical-application-of-clinical-trial-data-to-advanced-renal-cell-carcinoma/

The Bottom Line: Practical Application of Clinical Trial Data to Advanced Renal Cell Carcinoma – Summary:

Wesley A. Mayer, MD, reviews the landmark trials that set the standard of care for cytoreductive nephrectomy (CN) and the impact of targeted therapy on this technique. He discusses recent clinical trials on CN and targeted therapy, as well as data regarding cytoreductive partial nephrectomy.

Abstract:

Although the 5-year survival rate for localized kidney cancer is 93%, it is dismal for metastatic disease. Two landmark randomized prospective multicenter trials, a SWOG study and an EORTC study, demonstrated level 1 evidence for a survival benefit over interferon alone in 2001. This generated the adoption of CN into common practice.

However, the discovery of some of the mechanisms behind the molecular basis of kidney cancer resulted in a prolific growth of drug development. 

Ultimately, this led to approval of 11 novel agents for targeted treatment of metastatic kidney cancer between 2005 and 2018. This resulted in significant changes in the utilization of cytoreductive nephrectomy. Until recently, only retrospective data was available concerning the outcomes of cytoreductive nephrectomy in this new era of targeted therapy.

This presentation reviews 2 recent randomized multicenter prospective surgical trials and how their outcomes might impact the treatment of metastatic kidney in the future. The conversation also briefly covers feasibility and outcomes of cytoreductive partial nephrectomy.

About Innovations in Urologic Practice

Innovations in Urologic Practice (IUP) is an annual CME-accredited conference devoted to updating urologists on the rapidly changing healthcare environment. Topics focus on innovative diagnostic and treatment strategies, controversies, new and currently developing technologies, and challenges in today’s urologic practice. Dr. Mayer presented this lecture during the 23rd IUP in 2018. Please visit this page in order to learn more about future IUP meetings.